Dulaglutide
Trulicity
A GLP-1 receptor agonist built as a fusion of a GLP-1 analog to an antibody Fc fragment, which slows clearance enough to support once-weekly administration. Approved for glycemic control in type 2 diabetes.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
~5 days, subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied as a refrigerated single-dose prefilled pen or syringe; protect from light and do not freeze.
References
- FDA label: Trulicity (BLA 125469)
Read the source
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.